At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 75 enrolled
Drug / intervention
Zanubrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies
In Brief
A Phase 1 clinical trial evaluating Zanubrutinib and Tislelizumab for Lymphoma and Leukemia. Completed, enrolled 75 participants across 10 sites in 2 countries.
Detailed Summary
This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in participants with B-cell lymphoid malignancies.
Study Details
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJun 2016
Primary CompletionDec 2020
TodayJul 2026
First PostedJun 10, 2016
Enrollment StartJun 29, 2016
Primary CompletionDec 18, 2020
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 10.1 years ago
Interventions
Zanubrutinibdrug
Tislelizumabdrug